Brian Walker
Indiana University
TARGETING LOSS OF THE TUMOR SUPPRESSOR TENT5C IN MULTIPLE MYELOMA
View More
Raphael Szalat
Boston Medical Center
Molecular characterization and therapeutic targeting of Protein Kinase D2 in t(4;14) multiple myeloma
View More
Eric Smith
Dana-Farber Cancer Institute
Development of an optimized dual-targeted tandem VH-only fully-human CAR to generate long-term durable remission with adoptive cellular therapy for multiple myeloma
View More
Karl Petri
University Hospital Wurzburg
USB|CAR-T: Using CRISPR 2.0 to Generate Universal SLAMF7/BCMA CAR-T Cells for Treating Multiple Myeloma
View More
Max Merz
University of Leipzig
Single cell dissection of autologous apheresis products to predict successful manufacturing, safe application and response to chimeric antigen receptor T-cells in newly diagnosed and relapsed myeloma
View More
Andrew McPherson
Memorial Sloan Kettering Cancer Center
Improving Prognosis of Progression Risk in Multiple Myeloma Precursors through Single Cell Sequencing-Based Genomic and Immune Microenvironment Profiling
View More
Jose Angel Martinez-Climent
University of Navarra
Modeling, unraveling, and beating acquired resistance to BCMA and GPRC5D targeted agents in multiple myeloma
View More
Kylee Maclachlan
Memorial Sloan Kettering Cancer Center
Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy
View More
Tom Cupedo
Erasmus University Medical Center
Bone marrow inflammation as driver of multiple myeloma persistence and relapse
View More
Michele Cea
University of Genoa
TARGETING METABOLIC SWITCH OF HIGH-RISK MULTIPLE MYELOMA CELLS: TOWARDS THE DESIGN OF AN EXPLORATORY APPROACH FOR AN UNMET CLINICAL NEED
View More
Niccolo Bolli
Fundació Clínic per a la Recerca Biomèdica
Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE)
View More
Nizar Bahlis
University of Calgary
BCL2L1 armored CAR T cells overcome exhaustion and enhance persistence in multiple myeloma
View More
Noemi Puig
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, Spain
Application of mass spectrometry for the diagnosis and monitoring of real life patients with monoclonal gammopathies
View More
Jens Lohr
Dana-Farber Cancer Institute
LIQUID BIOPSY IN MYELOMA TO INFORM OUTCOME AND TREATMENT DECISIONS
View More
Gabriel Kwong
Georgia Tech Research Corporation
Democratizing multiple myeloma CAR T cell therapy by in situ programming of virus-specific T cells”
View More
Florian Kuchenbauer
Terry Fox Laboratory, BC Cancer Research Institute, Canada
Dissecting the functional role of APOBEC3B in multiple myeloma
View More
Sigurdur Kristinsson
University of Iceland
Early Detection and Intervention in Smoldering Multiple Myeloma: Population-Based Screening and Treatment (Edit-SMM)
View More
Jing Fu
Columbia University
Amyloid Targeting CAR Macrophage Therapy Against AL Amyloidosis
View More
Carlos Fernández de Larrea
Fundació Clínic per a la Recerca Biomèdica, Spain
Immunotherapy for Multiple Myeloma: A New Generation of Chimeric Antigen Receptors and Immune Checkpoint Blockade
View More
Francesca Cottini
Ohio State University
Improving immune surveillance in high-risk Multiple Myeloma patients
View More
Simone Cenci
Ospedale San Raffaele, Milan, Italy
Dissecting and appraising novel mitochondrial vulnerabilities against multiple myeloma
View More
Johannes Zakrzewski
Hackensack Meridian Health Center for Discovery and Innovation
Development of novel targeted therapies for multiple myeloma
View More
Julie O'Neal
Washington University in St. Louis
BCMA-iNKT-CAR for the Treatment of Multiple Myeloma
View More
Paola Neri
University of Calgary, Cumming School of Medicine, Calgary, Canada
Immunogenomics-guided adaptive cellular therapies in Multiple Myeloma
View More
Guido Marcucci
City of Hope
PNC-27: A Novel Effective Strategy for Targeting the Achilles’ Heel of Multiple Myeloma
View More
Shirong Li
Columbia University Medical Center
GCK, a new therapeutic target for undruggable RAS in myeloma treatment
View More
Florian Kuchenbauer
Terry Fox Laboratory, BC Cancer Research Institute, Canada
Exploring APOBECs as therapeutic vulnerabilities in Multiple Myeloma
View More
Zhiwei Hu
The Ohio State University
Targeting TF (CD142) as a new target for CAR-NK cell immunotherapy in multiple myeloma
View More
Kevin Hay
Terry Fox Laboratory, BC Cancer Research Institute, Canada
Chimeric antigen receptor T cells secreting IL-12 and anti-IL-6 to enhance responses in multiple myeloma
View More
Nicola Giuliani
University of Parma, Parma, Italy
Glutamine metabolism as new marker and diagnostic tool for bone diseases in mm patients
View More
Tom Cupedo
Erasmus MC Cancer Center, Rotterdam, the Netherlands
Targeting the bone marrow niche in Multiple Myeloma
View More
Simone Cenci
Ospedale San Raffaele, Milan, Italy
Discovering and targeting unprecedented mitochondrial vulnerabilities against multiple myeloma
View More
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
